" class="no-js "lang="en-US"> Huyabio International Collaboration with Bristol Myers Squibb in Melanoma - Medtech Alert
Wednesday, March 22, 2023

Breaking News

Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors Coya Therapeutics Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS) BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey Mindset Health Raises $12M to Expand Digital Hypnotherapy Apps & Scale Distribution GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey” Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis Gamida Cell Announces Changes to Board of Directors Newron Reports Topline Results From All Patients in Study Evaluating Evenamide as Add-on Therapy for Treatment-Resistant Schizophrenia Ascidian Therapeutics Appoints Jay A. Barth, M.D., as Chief Medical Officer TFS HealthScience Expands Operations into Israel, With Focus on Continuous, Rapid International Expansion
Huyabio International Collaboration with Bristol Myers Squibb in Melanoma | Pharmtech Focus

March 30 2021

Huyabio International Collaboration with Bristol Myers Squibb in Melanoma

HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, today announced that it had entered into a clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY) to evaluate the combination of HUYABIO’s HBI-8000, an epigenetic immunomodifier, and Opdivo® (nivolumab), a PD-1 blocking antibody. The Phase 3 trial is designed to evaluate the safety and efficacy of the combination in subjects with unresectable or metastatic melanoma not previously treated with anti-PD-1 therapy.

“This Phase 3 trial follows our open label Phase 2 study which showed impressive clinical results for the combination of Opdivo and HBI-8000 to treat melanoma,” said Dr. Mireille Gillings, CEO & Executive Chair of HUYABIO. “HBI-8000 has been shown to enhance the efficacy of Opdivo through one of its mechanisms of action that controls acetylation and nuclear transportation of PD-L1.”

HUYABIO will be the sponsor of the trial. Bristol Myers Squibb will provide Opdivo clinical drug supply for the study. Opdivo® is a registered trademark of Bristol Myers Squibb.

People In This Post

Mireille Gillings

Mireille Gillings

Companies In This Post

Huyabio International | Pharmtech Focus

Huyabio International
  1. Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors

    Appointments

     Read more
  2. Coya Therapeutics Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS)

    Clinical Trials

     Read more
  3. BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey

    News

     Read more
  4. Mindset Health Raises $12M to Expand Digital Hypnotherapy Apps & Scale Distribution

    Fundraising

     Read more
  5. GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”

    Diseases

     Read more
More On